• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

治疗人乳头瘤病毒相关恶性肿瘤的潜在治疗靶点

Potential Therapeutic Targets for the Treatment of HPV-Associated Malignancies.

作者信息

Lu Ziyao, Haghollahi Shahab, Afzal Muhammad

机构信息

Dartmouth Cancer Center, Manchester, NH 03104, USA.

出版信息

Cancers (Basel). 2024 Oct 14;16(20):3474. doi: 10.3390/cancers16203474.

DOI:10.3390/cancers16203474
PMID:39456568
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11506301/
Abstract

This review article aims to summarize broadly recent developments in the treatment of HPV-associated cancers, including cervical cancer and head and neck squamous cell carcinoma. Relatively new treatments targeting the key HPV E6 and E7 oncoproteins, including gene editing with TALENs and CRISPR/Cas9, are discussed. Given the increased immunogenicity of HPV-related diseases, other therapies such as PRR agonists, adoptive cell transfer, and tumor vaccines are reaching the clinical trial phase. Due to the mechanism, immunogenicity, and reversibility of HPV carcinogenesis, HPV-related cancers present unique targets for current and future therapies.

摘要

这篇综述文章旨在广泛总结人乳头瘤病毒（HPV）相关癌症治疗的最新进展，包括宫颈癌和头颈部鳞状细胞癌。文中讨论了针对关键HPV E6和E7癌蛋白的相对较新的治疗方法，包括使用转录激活样效应因子核酸酶（TALENs）和规律成簇间隔短回文重复序列/CRISPR相关蛋白9（CRISPR/Cas9）进行基因编辑。鉴于HPV相关疾病免疫原性的增加，其他疗法如模式识别受体（PRR）激动剂、过继性细胞转移和肿瘤疫苗正进入临床试验阶段。由于HPV致癌作用的机制、免疫原性和可逆性，HPV相关癌症为当前和未来的治疗提供了独特的靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbe0/11506301/1fdc5f223c48/cancers-16-03474-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbe0/11506301/1fdc5f223c48/cancers-16-03474-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbe0/11506301/1fdc5f223c48/cancers-16-03474-g001.jpg

相似文献

1
Potential Therapeutic Targets for the Treatment of HPV-Associated Malignancies.治疗人乳头瘤病毒相关恶性肿瘤的潜在治疗靶点
Cancers (Basel). 2024 Oct 14;16(20):3474. doi: 10.3390/cancers16203474.
2
Expression of human papillomavirus oncoproteins E6 and E7 inhibits invadopodia activity but promotes cell migration in HPV-positive head and neck squamous cell carcinoma cells.人乳头瘤病毒癌蛋白 E6 和 E7 的表达抑制 HPV 阳性头颈部鳞状细胞癌细胞中的侵袭伪足活性，但促进细胞迁移。
Cancer Rep (Hoboken). 2018 Oct;1(3):e1125. doi: 10.1002/cnr2.1125. Epub 2018 Jul 27.
3
EGFR-induced suppression of HPV E6/E7 is mediated by microRNA-9-5p silencing of BRD4 protein in HPV-positive head and neck squamous cell carcinoma.EGFR 诱导的 HPV E6/E7 抑制是通过 microRNA-9-5p 沉默 HPV 阳性头颈部鳞状细胞癌中的 BRD4 蛋白介导的。
Cell Death Dis. 2022 Nov 4;13(11):921. doi: 10.1038/s41419-022-05269-8.
4
Advanced Nanomedicine for High-Risk HPV-Driven Head and Neck Cancer.高危型 HPV 驱动的头颈部癌症的先进纳米医学。
Viruses. 2022 Dec 19;14(12):2824. doi: 10.3390/v14122824.
5
Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease.利用细菌CRISPR/Cas RNA引导的核酸内切酶使子宫颈癌细胞中的人乳头瘤病毒E6或E7基因失活。
J Virol. 2014 Oct;88(20):11965-72. doi: 10.1128/JVI.01879-14. Epub 2014 Aug 6.
6
Effects of Human Papilloma Virus E6/E7 Oncoproteins on Genomic Structure in Head and Neck Squamous Cell Carcinoma.人乳头瘤病毒E6/E7癌蛋白对头颈部鳞状细胞癌基因组结构的影响
Cancers (Basel). 2022 Dec 15;14(24):6190. doi: 10.3390/cancers14246190.
7
Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.针对人乳头瘤病毒 16（HPV16）和 HPV18 的 E6 和 E7 蛋白的 DNA 疫苗的开发，用于与重组痘苗增强和 PD-1 抗体联合免疫治疗。
mBio. 2021 Jan 19;12(1):e03224-20. doi: 10.1128/mBio.03224-20.
8
Involvement of aryl hydrocarbon receptor signaling in the development of small cell lung cancer induced by HPV E6/E7 oncoproteins.芳香烃受体信号通路在 HPV E6/E7 癌蛋白诱导的小细胞肺癌发生中的作用。
J Transl Med. 2011 Jan 4;9:2. doi: 10.1186/1479-5876-9-2.
9
HPV: Molecular pathways and targets.人乳头瘤病毒：分子途径与靶点
Curr Probl Cancer. 2018 Mar-Apr;42(2):161-174. doi: 10.1016/j.currproblcancer.2018.03.003. Epub 2018 Apr 5.
10
Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma.辐射增强人乳头瘤病毒16型的E6/E7转化致癌基因在人宫颈癌中的表达。
Cancer. 1998 Dec 1;83(11):2346-52. doi: 10.1002/(sici)1097-0142(19981201)83:11<2346::aid-cncr14>3.0.co;2-g.

引用本文的文献

1
Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions.实体瘤中CAR-T细胞疗法的进展：现状与未来方向
Cancers (Basel). 2025 Sep 3;17(17):2898. doi: 10.3390/cancers17172898.
2
Parvoviruses NS1 oncolytic attributes: mechanistic insights and synergistic anti-tumor therapeutic strategies.细小病毒NS1的溶瘤特性：机制见解与协同抗肿瘤治疗策略
Front Microbiol. 2025 Aug 11;16:1631433. doi: 10.3389/fmicb.2025.1631433. eCollection 2025.
3
New mouse model based on adenocarcinoma 4T1 cells expressing HPV16 E6 and E7 applied to assess the efficacy of therapeutic and prophylactic E6/E7-based HPV16 vaccines.

本文引用的文献

1
The HPV viral regulatory mechanism of TLRs and the related treatments for HPV-associated cancers.TLRs 介导的 HPV 病毒调控机制及其相关 HPV 相关性癌症的治疗方法。
Front Immunol. 2024 May 15;15:1407649. doi: 10.3389/fimmu.2024.1407649. eCollection 2024.
2
High-risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: Uncovering mechanisms of immune evasion and therapeutic prospects.高危型 HPV 致癌蛋白 E6 和 E7 及其与固有免疫反应的相互作用：揭示免疫逃逸的机制和治疗前景。
J Med Virol. 2024 Jun;96(6):e29685. doi: 10.1002/jmv.29685.
3
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia.
基于表达人乳头瘤病毒16型（HPV16）E6和E7的腺癌4T1细胞构建的新型小鼠模型，用于评估基于HPV16 E6/E7的治疗性和预防性疫苗的疗效。
Infect Agent Cancer. 2025 Jul 26;20(1):51. doi: 10.1186/s13027-025-00682-y.
4
Relationship Between Human Papilloma Virus and Upper Gastrointestinal Cancers.人乳头瘤病毒与上消化道癌症之间的关系
Viruses. 2025 Mar 4;17(3):367. doi: 10.3390/v17030367.
5
Exploring the metabolic alterations in cervical cancer induced by HPV oncoproteins: From mechanisms to therapeutic targets.探索人乳头瘤病毒癌蛋白诱导的宫颈癌代谢改变：从机制到治疗靶点
Biochim Biophys Acta Rev Cancer. 2025 Apr;1880(2):189292. doi: 10.1016/j.bbcan.2025.189292. Epub 2025 Mar 2.
社论：CRISPR-Cas9 治疗性基因编辑治疗镰状细胞病和输血依赖型β-地中海贫血的首次监管批准。
Med Sci Monit. 2024 Mar 1;30:e944204. doi: 10.12659/MSM.944204.
4
Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma.肿瘤浸润淋巴细胞治疗晚期黑色素瘤患者。
Nat Rev Clin Oncol. 2024 Mar;21(3):173-184. doi: 10.1038/s41571-023-00848-w. Epub 2024 Jan 8.
5
Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks.免疫检查点抑制剂的作用机制：环状 RNA 调控与癌症标志相关的见解。
Cell Death Dis. 2024 Jan 4;15(1):3. doi: 10.1038/s41419-023-06389-5.
6
mRNA-HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV-mediated cancers via subcutaneous immunization.mRNA-HPV 疫苗通过皮下免疫，提高了 HPV 介导癌症的治疗潜力，编码 E6 和 E7。
J Med Virol. 2023 Dec;95(12):e29309. doi: 10.1002/jmv.29309.
7
mRNA-LNP vaccination-based immunotherapy augments CD8 T cell responses against HPV-positive oropharyngeal cancer.基于mRNA-LNP疫苗接种的免疫疗法增强了针对HPV阳性口咽癌的CD8 T细胞反应。
NPJ Vaccines. 2023 Sep 29;8(1):144. doi: 10.1038/s41541-023-00733-8.
8
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends.实体瘤的免疫检查点治疗：临床困境与未来趋势。
Signal Transduct Target Ther. 2023 Aug 28;8(1):320. doi: 10.1038/s41392-023-01522-4.
9
Predictive impact of human papillomavirus circulating tumor DNA in treatment response monitoring of HPV-associated cancers; a meta-analysis on recurrent event endpoints.循环肿瘤 HPV DNA 对 HPV 相关癌症治疗反应监测的预测影响：针对复发性事件终点的荟萃分析。
Cancer Med. 2023 Sep;12(17):17592-17602. doi: 10.1002/cam4.6377. Epub 2023 Jul 26.
10
Anti-HPV16 oncoproteins siRNA therapy for cervical cancer using a novel transdermal peptide PKU12.使用新型透皮肽PKU12进行抗人乳头瘤病毒16型癌蛋白小干扰RNA治疗宫颈癌
Front Oncol. 2023 Jun 7;13:1175958. doi: 10.3389/fonc.2023.1175958. eCollection 2023.